NATA launches quarterly newsletter
We’re excited to announce the launch of the NATA Newsletter—a new quarterly update highlighting our latest research, collaborations, and community engagement in the field of nucleic acid therapeutics.
Read the latest issue: NATA Newsletter: 2025 Q1 – View in Archive
Sign up to receive future editions: Subscribe to the NATA Newsletter
In this issue:
Targeting juvenile dermatomyositis (JDM)
Learn how NATA scientists are developing oligonucleotide-based therapies to reduce interferon beta activity—a key driver of inflammation in JDM. This approach represents a promising step toward safer, more targeted treatments for autoimmune muscle diseases.
Highlights from the first OTS India regional meeting
We share insights from this landmark event, which gathered researchers and biotech leaders from 15 countries. The meeting showcased cutting-edge work in nucleic acid therapeutics and reinforced global momentum in the field.
Stories from the NATA community
Discover how we’re supporting Rare Disease Day and get to know our visiting scientist, Dr Shalini Gupta, through a special Q&A, reflecting on her research journey and collaboration with NATA.
We hope you’ll join our mailing list to stay up-to-date with everything happening at NATA as we work to accelerate the development of nucleic acid therapies.